Shots:
- Syndivia has granted GSK exclusive global rights to develop and commercialize a preclinical ADC for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
- As per the deal, GSK will handle global development, manufacturing, & commercialization of the ADC in exchange for an upfront payment, along with development & commercial milestone payments up to a total of £268M ($356.6M), plus tiered royalties
- The ADC leverages Syndivia’s GeminiMab conjugation technology & showed superior anti-tumor activity & a favorable safety profile in preclinical studies by effectively shrinking tumors without added toxicity, even at higher doses
Ref: GSK | Image: GSK & Syndivia | Press Release
Related News:- GSK’s Blenrep (Belantamab Mafodotin) Regimen Receives the US FDA’s Approval to Treat R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
